Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune

Published:2017-12 Issue: Volume:96 Page:378-383
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Jiang Zhansheng,Yang Yanfang,Yang Yinli,Zhang Yu,Yue Zhensong,Pan Zhanyu,Ren Xiubao

Funder

National Key Clinical Specialist Construction Programs of China

CSCO-LiZhu Chinese Medicine foundation for cancer research

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference39 articles.

1. Cancer statistics in China, 2015;Chen;CA Cancer J. Clin.,2016

2. Cancer statistics 2016;Siegel;CA: Cancer J. Clin.,2016

3. Osimertinib for pretreated EGFR thr790met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study;Goss;Lancet Oncol.,2016

4. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;New Engl. J. Med.,2014

5. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer;Scagliotti;J. Clin. Oncol.,2008

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the antimicrobial activity of rare ginsenosides and the progress of their related pharmacological effects;Phytomedicine;2024-10

2. Ginsenoside Rg3 targets glycosylation of PD-L1 to enhance anti-tumor immunity in non-small cell lung cancer;Frontiers in Immunology;2024-08-23

3. Research progress on the influence of traditional Chinese medicine on tumor microenvironment therapy;New Updates in Tumor Microenvironment [Working Title];2024-08-14

4. Ginsenosides in cancer: Proliferation, metastasis, and drug resistance;Biomedicine & Pharmacotherapy;2024-08

5. A pH-triggered N-oxide polyzwitterionic nano-drug loaded system for the anti-tumor immunity activation research;Journal of Nanobiotechnology;2024-07-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3